Clinical · CREA-CLIN-02 · v2
The studies here point in different directions. In two small trials, people given creatine on top of talking therapy or an antidepressant improved somewhat more than those given a dummy pill [1][4]. But a trial in people with bipolar depression found no difference on its main depression measure [2], and creatine given on its own to healthy older women changed their mood not at all [6]. In every case where creatine seemed to help, it was added to another treatment, so its effect by itself was never separated out. The trials were also small, short and described by their own authors as early-stage. Taken together the evidence hints at a possible benefit as an add-on but does not pin one down.
Two small adjunctive randomised trials report a positive direction: creatine added to cognitive-behavioural therapy lowered PHQ-9 by a mean difference of -5.12 versus placebo [1], and creatine augmentation of escitalopram produced greater improvement in depressive symptoms in women with major depressive disorder [4]. A bipolar proof-of-concept trial found no significant group difference on its primary MADRS endpoint (p = 0.560; Cohen's d = 0.231), with the positive signal confined to a secondary remission threshold [2]. Creatine alone produced no change on the Geriatric Depression Scale in healthy older women, where the mood benefit came from strength training (p = 0.60 for creatine vs placebo) [6]. A dose-ranging study reported only that frontal-lobe phosphocreatine was inversely correlated with depression scores (p = 0.02), a target-engagement signal rather than a demonstrated symptom reduction [5], and a mechanistic study's human result reduced depression scores only when creatine was co-administered with Bifidobacterium [11]. The contested point: The division is whether the directionally positive adjunctive results [1][4] reflect creatine's own antidepressant action or the co-administered treatment, given that the one dedicated monotherapy test was null [6] and the one bipolar trial missed its primary endpoint [2]. The panel reads the same corpus as a genuine but weak and confounded signal rather than an established effect.
All 11 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Creatine, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The strongest positive trial [1] is explicitly a pilot/feasibility, 'hypothesis-generating' study; such effect sizes are unreliable and the authors call for longer, larger trials.
The dedicated bipolar proof-of-concept [2] was null on its primary MADRS endpoint (p=0.560); the positive claim rests on a secondary remission-threshold analysis, a selective-emphasis risk.
Where it remains uncertain. The bipolar proof-of-concept was null on its primary MADRS endpoint (p = 0.560) [2] and creatine alone changed nothing in healthy older women [6], so every positive result is adjunctive and confounded.
Aleatory
Trials of N=18-100 [1][2][4][6] carry wide sampling variability, so observed effect sizes are unstable estimates.
Epistemic
No large, long RCT exists in the corpus; [1] itself calls for longer and larger trials, leaving the effect unconfirmed.
Inferential
[5] reports a phosphocreatine-to-depression-score correlation (p = 0.02), a biomarker rather than a measured symptom reduction.
The load-bearing papers from a corpus of 11, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Supports the claim: adjunctive creatine reduced depression scores more than placebo in a pilot RCT (N=100)
“At 8 weeks, PHQ-9 scores were lower in both study arms, but significantly more so in participants taking creatine (mean difference= -5.12).”
Panel auditInternal validity: medium · scope of inference: Adults with depression (mean PHQ-9 17.6) receiving CBT in an under-resourced setting; creatine as adjunct to CBT, not monotherapy.Key limitations: pilot feasibility design · creatine combined with CBT not isolated · single short 8-week window
Weakens the claim: primary depression endpoint null in bipolar depression (N=35)
“We did not find a statistically significant difference in the comparison between groups for the change in score on the MADRS after 6 weeks in an intention-to-treat (ITT) analysis (p = 0.560; Cohen's d = 0.231).”
Panel auditInternal validity: medium · scope of inference: Patients with bipolar I or II in a depressive episode on regular medication; adjunctive creatine.Key limitations: small sample · null primary outcome · two creatine patients switched to hypomania/mania · bipolar not unipolar depression
Supports the claim as adjunct to SSRI in women with MDD (N=52)
“Improvement in depressive symptoms was greater in patients receiving creatine augmentation relative to placebo augmentation.”
Panel auditInternal validity: medium · scope of inference: Women with MDD receiving escitalopram; creatine as augmentation, not monotherapy.Key limitations: no significance stated for symptom outcome · women-only · augmentation of SSRI not standalone · imaging-focused design
Indirect/mechanistic support: target engagement correlated with depression severity, not an efficacy endpoint
“frontal lobe PCr was inversely correlated with depression scores (p = 0.02).”
Panel auditInternal validity: low · scope of inference: Adolescent females with SSRI-resistant MDD; mechanistic target engagement of brain bioenergetics.Key limitations: mechanistic/correlational endpoint · no symptom-change group contrast · sample size not reported · adolescent females only
4 of 11 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A genuine but weak and confounded positive signal from pilot adjunctive trials, offset by a null primary endpoint and a null monotherapy result, supports only an Uncertain verdict.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Creatine monotherapy in active depression. Every positive result is adjunctive, so creatine's independent effect on depressed patients is never measured [1][4][6][11]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A placebo-controlled RCT of creatine alone versus placebo in patients with current major depressive disorder, with a validated symptom scale as the primary endpoint.
Open question: Does creatine reduce depression symptoms on its own, without a co-administered antidepressant or therapy? Why it is still open: Only the adjunctive trials [1][4][11] were positive, and the sole monotherapy test [6] was null in a non-depressed population.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19